儿童BCP-ALL伴低二倍体或BCR::ABL1融合接受异基因HSCT的结局:FORUM研究结果
FORUM前瞻性试验纳入741例≥4岁接受HLA相合同胞供者HSCT的BCP-ALL患者(2013-2023),比较伴低二倍体、BCR::ABL1融合与无这两类遗传病变患者的移植后结局。三组3年OS和EFS无显著差异,但低二倍体CR2患者OS和EFS较差,BCR::ABL1+患者结局良好,移植后预防性TKI改善EFS并降低CIR。
要点
- BCR::ABL1融合、低二倍体与无这两类病变三组3年OS和EFS无显著差异。
- 低二倍体CR2患者OS和EFS较差,非复发死亡仅见于近二倍体病例。
- 移植前MRD阳性在所有遗传组均预测更差OS、EFS和CIR。
核心结论
- 标准化的FORUM方案在各遗传亚组间取得可比结局,移植后TKI维持治疗改善BCR::ABL1+ BCP-ALL的结局。
研究设计与样本
- 前瞻性FORUM试验纳入741例年龄≥4岁、接受HLA相合供者HSCT的BCP-ALL患者(2013-2023年),比较伴低二倍体、BCR::ABL1融合与无这两类遗传病变患者的移植后结局。
- 多因素分析评估与总生存(OS)、无事件生存(EFS)和累积复发率(CIR)的关联。
- 同时评估移植前和移植后附加治疗(包括酪氨酸激酶抑制剂TKI和免疫治疗)的使用。
主要发现
- BCR::ABL1融合、低二倍体与无这两类遗传病变患者之间的3年OS和EFS无显著差异。
- 第二次完全缓解(CR2)的低二倍体BCP-ALL患者OS和EFS较差,驱动因素为非复发死亡(NRM)较高,NRM仅见于近二倍体病例。
- 接受全身照射预处理的严重低二倍体病例未发生NRM。
- 移植时MRD阳性在所有遗传组均预测更差OS、EFS和CIR。
- 低二倍体BCP-ALL患者复发后难以挽救,即使使用嵌合抗原受体T细胞治疗。
关键数值与推荐
- BCR::ABL1+患者结局良好,即使移植前MRD阳性。
- 移植后预防性TKI使用改善EFS并降低CIR。
- CR2接受移植的BCR::ABL1+患者3年OS为96%。
临床怎么用
- 移植前MRD阳性在所有遗传组均预测更差OS、EFS和CIR。
- 移植后预防性TKI使用改善BCR::ABL1+患者EFS并降低CIR。
- 低二倍体BCP-ALL患者复发后难以挽救,即使使用嵌合抗原受体T细胞治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypodiploid and BCR::ABL1+ B-cell precursor acute lymphoblastic leukemia (BCP-ALL) confers a high risk of disease relapse. We investigated post-hematopoietic stem cell transplantation (HSCT) outcomes within the prospective FORUM trial, comparing outcomes among these genetic subgroups with those of patients without these lesions. The use of pre- and post-HSCT add-on treatments, including tyrosine kinase inhibitors (TKI) and immunotherapies, was also assessed. Multivariate analysis evaluated associations with overall survival (OS), event-free survival (EFS), and cumulative incidence of relapse (CIR). The FORUM trial enrolled 741 patients aged ≥4 years with BCP-ALL who underwent HSCT from HLA-matched donors (2013-2023). The 3-year OS and EFS did not differ significantly between patients with BCR::ABL1 fusion, hypodiploidy, and neither of these 2 genetic lesions. However, patients with hypodiploid BCP-ALL in second complete remission (CR2) showed inferior OS and EFS, driven by higher nonrelapse mortality (NRM), which occurred exclusively in near-diploid cases. No NRM occurred in severe hypodiploid cases conditioned with total body irradiation. Minimal residual disease (MRD) positivity at transplant predicted worse OS, EFS, and CIR in all genetic groups. Patients with hypodiploid BCP-ALL were difficult to salvage after relapse, even with chimeric antigen receptor T-cell therapy. By contrast, BCR::ABL1+ patients had favorable outcomes, even when MRD positive before HSCT. Prophylactic TKI use after HSCT improved EFS and reduced CIR. BCR::ABL1+ patients who received a transplant in CR2 had a 3-year OS of 96%. In conclusion, the standardized FORUM protocol yielded comparable outcomes across genetic subgroups. Posttransplant TKI maintenance improved outcomes in BCR::ABL1+ BCP-ALL. This trial was registered at www.clinicaltrials.gov as #NCT01949129 and at www.clinicaltrialsregister.eu as #EudraCT2012-0032-22.
引用
- Buechner J, Poetschger U, Bader P, et al. Outcomes of BCP-ALL with hypodiploidy or BCR::ABL1 fusion in children undergoing allogeneic HSCT: results from the FORUM study. Blood. 2026. PMID: 41259231. doi:10.1182/blood.2025030951
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。